Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
API Innovation Center tells Missouri committee it can help reshore generic drug production
Summary
The API Innovation Center presented data to the Missouri Emerging Issues Committee arguing that the U.S. relies heavily on foreign sources for generic active pharmaceutical ingredients and that existing U.S. manufacturing capacity can be activated with targeted investment, contracts and partnerships.
Tony Sardela, president and CEO of the API Innovation Center, told the Missouri Emerging Issues Committee that the organization’s work focuses on the data and business models needed to bring active pharmaceutical ingredient (API) manufacturing back to the United States.
Sardela said the API is “the component in a medicine that makes it effective for treatment,” and presented three findings from the center’s research: more than 91% of prescriptions in the U.S. are for generics; 83% of the top 100 prescribed medicines have no U.S. source for their active ingredient; and about one-quarter of foreign production for those medicines is from facilities…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
